abs155.txt	purpose		advanced	pancreatic	cancer	is	a	highly	refractory	disease	almost	alwaysassociated	with	survival	of	little	more	than	year	new	interventions	based	onnovel	targets	are	needed	we	aim	to	identify	genetic	determinants	overallsurvival	(os)	in	patients	after	treatment	gemcitabine	using	genome-widescreens	germline	dna	also	support	these	findings	vitrofunctional	analysis	and	methods	genome-wide	screens	two	independentcohorts	(from	the	leukemia	group	b(calgb)	80303	mayo	clinic)	were	used	select	genes	associated	withos	vitamin	d	receptor	gene	(vdr)	was	selected	interactions	ofgenetic	variation	vdr	circulating	levels	gemcitabinetreatment	evaluated	functional	effects	common	variants	alsoevaluated	experimental	assays	human	cell	lines	results	rs2853564	variant	os	fromboth	clinic	(hr	0	81	95%	ci	70-0	94	p	=	0059)	calgb	(hr0	74	63-0	87	0002)	interacted	high	pre-treatment	levelsof	25-hydroxyvitamin	(25(oh)d	measure	endogenous	d)	(p	0079for	interaction)	024	for	toconfer	increased	transcriptional	activity	luciferaseassays	reduced	binding	irf4	transcription	factor	conclusion	our	propose	as	novel	determinant	inadvanced	this	genemight	interact	determineimproved	patient	evidence	modulatory	roleof	pathway
